Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

152
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
152
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

237
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
237
Depression: Overview01:18

Depression: Overview

316
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
316
The Placebo Effect01:54

The Placebo Effect

6.2K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.2K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

189
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and tolerability of nutraceuticals and phytotherapics for antipsychotic-induced weight gain in schizophrenia spectrum disorders: Systematic review and meta-analysis.

Pharmacopsychiatry·2026
Same author

Serum benzylpenicillin levels during treatment for amatoxin poisoning: pharmacokinetic support for OATP1B3 inhibition.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Treatment and management approaches for ketamine misuse: A systematic review of medical interventions.

Journal of substance use and addiction treatment·2026
Same author

Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin.

Brain sciences·2026
Same author

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

Cephalalgia : an international journal of headache·2026
Same author

Supporting the Implementation and Addressing the Challenges of the EU HTA Regulation.

Journal of market access & health policy·2026

Related Experiment Video

Updated: Aug 13, 2025

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.6K

Psilocybin for Depression: From Credibility to Feasibility, What's Missing?

Antonio Munafò1, Davide Arillotta2,3, Guido Mannaioni2

  • 1Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, 95123 Catania, Italy.

Pharmaceuticals (Basel, Switzerland)
|January 21, 2023
PubMed
Summary

Psilocybin shows promise for treating various psychiatric disorders, including depression, through psychedelic-assisted psychotherapy. However, further research is needed to address limitations and challenges for its clinical application.

Keywords:
clinical trialsdepressionethical concernsmethodological issuespsilocybin

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

762
Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice
06:08

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

9.3K

Related Experiment Videos

Last Updated: Aug 13, 2025

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.6K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

762
Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice
06:08

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

9.3K

Area of Science:

  • Psychiatry and Neuroscience
  • Psychopharmacology
  • Clinical Psychology

Background:

  • Psilocybin is emerging as a potential transdiagnostic therapeutic agent for diverse psychiatric conditions.
  • Psychedelic-assisted psychotherapy has demonstrated efficacy in alleviating depressive symptoms.
  • Existing studies face limitations such as small sample sizes, blinding issues, and restricted follow-up periods.

Purpose of the Study:

  • To critically evaluate the clinical and methodological challenges associated with psilocybin therapy.
  • To propose potential solutions and future directions for psilocybin research and application.
  • To assess the transdiagnostic therapeutic potential of psilocybin.

Main Methods:

  • Review of current literature on psilocybin in psychiatric treatment.
  • Analysis of study limitations, including sample characteristics and methodological rigor.
  • Examination of health, political, and ethical considerations surrounding psilocybin use.

Main Results:

  • Significant limitations exist in current psilocybin research, impacting definitive conclusions.
  • Challenges include practitioner experience, lack of standardized protocols, legal status, and potential adverse effects.
  • Despite limitations, psilocybin therapy shows promise for sustained symptom alleviation.

Conclusions:

  • Addressing methodological and clinical issues is crucial for understanding psilocybin's therapeutic potential.
  • Future research requires more robust protocols, larger sample sizes, and longer follow-up periods.
  • Potential reclassification and policy changes may facilitate broader clinical acceptance and application of psilocybin.